Last reviewed · How we verify
cholinesterase inhibitors
At a glance
| Generic name | cholinesterase inhibitors |
|---|---|
| Also known as | No applicable |
| Sponsor | Federal University of Minas Gerais |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Oedema peripheral
- Anaemia
Key clinical trials
- Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease (PHASE2)
- Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease (EARLY_PHASE1)
- Masitinib in Patients With Mild Alzheimer's Disease (PHASE3)
- Effect of Donepezil on Speech Recognition in Cochlear Implant Users (EARLY_PHASE1)
- CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease) (PHASE3)
- Effect of Acetylcholinesterase Inhibitors on Bone Metabolism (PHASE2)
- Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research
- Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cholinesterase inhibitors CI brief — competitive landscape report
- cholinesterase inhibitors updates RSS · CI watch RSS
- Federal University of Minas Gerais portfolio CI